Sommario

• • ·Introduction

    Pagina :1-2

    Bramah N Singh

     
• • ·Overview of trends in the control of cardiac arrhythmia: past and future

    Pagina :3-10

    Bramah N Singh

    Mappa Mappa  
• • ·Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions

    Pagina :11-19

    Stanley Nattel, Bramah N Singh

    Riassunto Riassunto Mappa Mappa  
• • ·Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent

    Pagina :20-28

    Itsuo Kodama, Kaichiro Kamiya, Junji Toyama

    Riassunto Riassunto Mappa Mappa  
• • ·Mechanisms underlying variability in response to drug therapy: implications for amiodarone use

    Pagina :29-36

    Dan M Roden

    Riassunto Riassunto Mappa Mappa  
• • ·Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations

    Pagina :37-45

    P.Timothy Pollak

    Riassunto Riassunto Mappa Mappa  
• • ·Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation

    Pagina :46-51

    Peter R Kowey, Roger A Marinchak, Seth J Rials, David B Bharucha

    Riassunto Riassunto Mappa Mappa
• • ·Intravenous antiarrhythmic drug therapy in the resuscitation from refractory ventricular arrhythmias

    Pagina :52-55

    Peter J Kudenchuk

    Riassunto Riassunto  
• • ·Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation

    Pagina :56-62

    Stefan H Hohnloser

    Riassunto Riassunto Mappa Mappa  
• • ·Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias

    Pagina :63-68

    Adam Zivin, Gust H Bardy

    Riassunto Riassunto Mappa Mappa
• • ·Concomitant device and drug therapy: current trends, potential benefits, and adverse interactions

    Pagina :69-75

    Francis E Marchlinski, Erica S Zado, Megan P Deely, Josephine Saligan, Manisha Ashar, Hemal Nayak

    Riassunto Riassunto Mappa Mappa  
• • ·Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone

    Pagina :76-82

    Kofo O Ogunyankin, Bramah N Singh

    Riassunto Riassunto Mappa Mappa  
• • ·Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs

    Pagina :83-89

    Yee Guan Yap, A.John Camm

    Riassunto Riassunto Mappa Mappa  
• • ·Meta-analysis of antiarrhythmic drug trials

    Pagina :90-93

    Stuart J Connolly

    Riassunto Riassunto Mappa Mappa  
• • ·Beta-adrenergic blocker mortality trials in congestive heart failure

    Pagina :94-102

    John R Teerlink, Barry M Massie

    Riassunto Riassunto Mappa Mappa
• • ·Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy

    Pagina :103-108

    Steven N Singh, Ross D Fletcher

    Riassunto Riassunto Mappa Mappa  
• • ·Class III antiarrhythmic agents in cardiac failure: lessons from clinical trials with a focus on the grupo de estudio de la sobrevida en la insuficiencia cardiaca en Argentina (GESICA)

    Pagina :109-114

    Hernan C Doval

    Riassunto Riassunto Mappa Mappa  
• • ·Evolution of diagnostic and interventional cardiac electrophysiology: a brief historical review

    Pagina :115-124

    Gregory K Feld

    Riassunto Riassunto Mappa Mappa  
• • ·Mechanisms of atrial fibrillation and flutter and implications for management

    Pagina :125-130

    Peng-Sheng Chen, Charles A Athill, Tsu-Juey Wu, Takanori Ikeda, James J.C Ong, Hrayr S Karagueuzian

    Riassunto Riassunto Mappa Mappa  
• • ·Epidemiology and significance of atrial fibrillation

    Pagina :131-138

    Kathryn M Ryder, Emelia J Benjamin

    Riassunto Riassunto Mappa Mappa
• • ·Efficacy and safety of septal and left-atrial linear ablation for atrial fibrillation

    Pagina :139-146

    Pierre Jaı̈s, Dipen C Shah, Michel Haı̈ssaguerre, Atsushi Takahashi, Thomas Lavergne, Méléze Hocini, Stéphane Garrigue, Serge S Barold, Philippe Le Métayer, Jacques Clémenty

    Riassunto Riassunto Mappa Mappa  
• • ·Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation

    Pagina :147-151

    Isabelle C Van Gelder, Anton E Tuinenburg, Bas S Schoonderwoerd, Robert G Tieleman, Harry J.G.M Crijns

    Riassunto Riassunto Mappa Mappa  
• • ·Intravenous antiarrhythmic regimens with focus on amiodarone for prophylaxis of atrial fibrillation after open heart surgery

    Pagina :152-155

    Thomas Guarnieri

    Riassunto Riassunto Mappa Mappa  
• • ·Prevention of atrial fibrillation in the postoperative cardiac patient: significance of oral class III antiarrhythmic agents

    Pagina :156-160

    Fred Morady

    Riassunto Riassunto Mappa Mappa  
• • ·Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization

    Pagina :161-173

    Bramah N Singh, Freny Vaghaiwalla Mody, Becky Lopez, Jonnalagedda S.M Sarma

    Riassunto Riassunto Mappa Mappa